You're viewing: GranaGard – Nano-Omega 5
$49.00You're viewing: GranaGard – Nano-Omega 5
$49.00
Granlix aims to provide its customers with products based on science and nature. The company’s laboratories are managed by Prof. Ruth Gavizon from Hadassah Hospital and Prof. Shlomo Magdessi from the Hebrew University. The company’s laboratories conduct studies on various models for the purpose of examining the safety of the company’s products and their effect. These studies have been published in leading scientific journals after careful peer review.
Relevant studies in the company’s products are also applied in clinical trials on humans, in close cooperation with the departments of neurology at Hadassah Hospital and Ichilov Hospital, as well as with the neuropsychology department at Rambam Hospital and a research institute in Mexico.
The trial in humans was conducted at Hadassah Ein Kerem University Hospital in Jerusalem, by Prof. Dimitrius Krosis, an internationally renowned neurologist, along with Dr. Panayiota Petrou. The trial was approved by the Helsinki Committee for Clinical Trials in Humans and the hospital’s management. It was found that people who took GranaGard for 3 months only, reflected a 12% improvement in the CVLT-II test which measures cognitive memory abilities.
Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients
P. Petrou MD, A. Ginzberg PhD., O. Binyamin PhD. and D. Karussis MD, PhD.
Nano-PSO Administration Attenuates Cognitive and Neuronal Deficits Resulting from Traumatic Brain Injury
D Qubty, K Frid, M Har-Even, V Rubovitch, R Gabizon
Comparing anti–aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease
O Binyamin, K Frid, G Keller, A Saada, R Gabizon
Punica granatum L.-derived omega-5 nanoemulsion improves hepatic steatosis in mice fed a high fat diet by increasing fatty acid utilization in hepatocytes
K. Zamora-López, L. G. Noriega, A. Estanes-Hernández, I. Escalona-Nández, S. Tobón-Cornejo, A. R. Tovar, V. Barbero-Becerra & C. Pérez-Monter
Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice
O Binyamin, K Nitzan, K Frid, Y Ungar, H Rosenmann, R Gabizon
Mitochondrial dysfunction in preclinical genetic prion disease: A target for
preventive treatment?
G Keller, O Binyamin, K Frid, A Saada, R Gabizon
Continues administration of Nano-PSO significantly increased survival of genetic CJD mice
Binyamin O, Keller G, Frid K, Larush L, Magdassi S, Gabizon R.
Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant
Binyamin O, Larush L, Frid K, Keller G, Friedman-Levi Y, Ovadia H, Abramsky O, Magdassi S, Gabizon R
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
